ArKal grabs $17.5m for blood glucose monitor tech
This article was originally published in Clinica
Continuous blood glucose monitoring specialist ArKal Medical has raised $17.5m in a series B financing round led by Thomas McNerney & Partners. Delphi Ventures and MedVenture Associates, both existing shareholders in Fremont, California-based ArKal, also made significant contributions. ArKal, which is in stealth mode, said it will use the new funding to advance "the next stage of corporate and product milestones".